Public Health Impact of Paxlovid as Treatment for COVID-19, United States.

Authors:
Bai Y; Du Z; Wang L; Lau EHY; Fung IC and 5 more

Journal:
Emerg Infect Dis

Publication Year: 2024

DOI:
10.3201/eid3002.230835

PMCID:
PMC10826746

PMID:
38181800

Journal Information

Full Title: Emerg Infect Dis

Abbreviation: Emerg Infect Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Communicable Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Evidence found in paper:

"additional information about public health impact of paxlovid as treatment for covid-19 united states the computer code referenced in this study is available from github ( https://github com/zhanweidu/pax )."

Evidence found in paper:

"Financial support was provided by the AIR@InnoHK Programme from Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, the US National Institutes of Health (grant no. R01 AI151176), the Centers for Disease Control and Prevention COVID Supplement (grant no. U01IP001136), Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region (grant no. 21200632) and National Natural Science Foundation of China (grant no. 82304204). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. B.J.C. consults for AstraZeneca, GSK, Moderna, Roche, Sanofi Pasteur, and Pfizer. "

Evidence found in paper:

"Financial support was provided by the AIR@InnoHK Programme from Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, the US National Institutes of Health (grant no. R01 AI151176), the Centers for Disease Control and Prevention COVID Supplement (grant no. U01IP001136), Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region (grant no. 21200632) and National Natural Science Foundation of China (grant no. 82304204). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025